Answers are grounded in this paper and cite their sources.
Drugs targeting the molecular mechanism underlying integrin β₁-mediated signaling may represent a novel therapeutic approach for treating fibroproliferative disorders. Clinical trials directly testing this hypothesis are warranted.
No takes yet. Share an insight, caveat, or question.
Andrew Leask (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: